# Extraction of *gamma*-Hydroxybutyric Acid (GHB) from Urine Using ISOLUTE<sup>®</sup> SLE+ Prior to GC/MS Analysis




Figure 1. Structure of gamma-Hydroxybutyric acid (GHB)

#### Analytes

Gamma-Hydroxybutyric acid (GHB) & GHB-D6

### Sample Preparation Procedure

#### Introduction

This application note describes the extraction of GHB from urine using supported liquid extraction and subsequent analysis by GC/MS.

ISOLUTE<sup>®</sup> SLE+ Supported Liquid Extraction plates and columns offer an efficient alternative to traditional liquid-liquid extraction (LLE) for bioanalytical sample preparation, providing high analyte recoveries, no emulsion formation, and significantly reduced sample preparation.

Sample Pre-treatment:	Dilute pre-treated urine (0.2 mL) with 0.2% formic acid (aq) (0.2 mL). Spike GHB-D6 internal standard and vortex mix thoroughly.		
Format:	ISOLUTE° SLE+ 200 $\mu L$ Fixed Well Plate, part number 820-0200-P01		
Sample Loading:	Load the pre-treated urine (200 $\mu$ L total volume) onto each well and apply a pulse of vacuum or positive pressure (3–5 seconds) to initiate flow. Allow the sample to absorb for 5 minutes.		
Analyte Extraction:	Apply ethyl acetate (1 mL) and allow to flow under gravity for 5 minutes. Apply vacuum or positive pressure to pull through any remaining extraction solvent (5–10 seconds).		
Format:	ISOLUTE°SLE+ 400 µL Sample Capacity columns, part number 820-0055-B		
Sample Loading:	Load the pre-treated urine (200 $\mu$ L total volume*) onto the column and apply a pulse of vacuum or positive pressure (3–5 seconds) to initiate flow. Allow the sample to absorb for 5 minutes.		
	*Note: Column is underloaded		
Analyte Extraction:	Apply ethyl acetate (1 mL) and allow to flow under gravity for 5 minutes. Apply a further aliquot of ethyl acetate (1 mL) and allow to flow for another 5 minutes under gravity. Apply vacuum or positive pressure to pull through any remaining extraction solvent (5–10 seconds).		
Post Elution, Reconstitution and Derivatisation:	Dry the extract in a stream of air or nitrogen at ambient temperature using a SPE Dry (20 to 40 L/min) or TurboVap (1.0 bar) for 30 mins.		
	Upon dryness, reconstitute with ethyl acetate (50 $\mu$ L) and BSTFA/1% TMCS (50 $\mu$ L) and vortex for 20 seconds. Transfer to a high recovery glass vial.		



## GC Conditions

Instrument:	Agilent 7890A with QuickSwap		
Column:	Phenomenex Zebron ZB-35, 30 m x 0.25 mm ID x 0.25 $\mu m$		
Carrier	Helium 1.2 mL/min (constant flow)		
Inlet:	250 °C, Split (ratio 10:1), 12 mL/min, septum purge flow: 3 mL/min		
Injection:	1 μL		
Wash Solvent:	Ethyl acetate		
Oven:	Initial temperature 70 °C		
	Ramp 10 °C/min to 140 °C		
	Ramp 120 °C/min to 350 °C		
Post Run:	Back-flush for 1.6 minutes (2 void volumes)		
Transfer Line:	280 °C		

### **MS** Conditions

Instrument:	Agilent 5975C	
Source:	230 °C	
Quadrupole:	150 °C	
MSD mode:	SIM	

### **SIM Parameters**

 Table 1. Ions acquired in the selected Ion Monitoring (SIM) mode

SIM Group	Analyte	Quantifier Ion	Quantifier Ion
1	GHB-D6	239	240
1	GHB	233	117

### Results

The optimized protocols for ISOLUTE SLE+ plates and columns demonstrated reproducible recoveries between three unique donors, as shown in Figure 2. Percentage recovery was 52-69%. RSDs for GHB were below 9% on the 200 µL capacity plate format and below 4% on 400 µL capacity column format. **Figure 3**. shows linearity data for plate and column formats ( $r^2$ >0.999 for both formats). This application is unusual because of the relatively high concentration cut-off requirement ( $10 \mu g/mL$ ) for illicit GHB. The low matrix volume used and relatively low recoveries do not adversely affect the required assay performance and sufficient sensitivity was achieved.







Figure 2. Typical analyte % extraction recoveries (n=7) using the ISOLUTE<sup>\*</sup> SLE+ protocol using 200  $\mu$ L capacity plate format (left) and 400  $\mu$ L capacity column format (right)



**Figure 3.** Calibration curves for extracted levels of spiked urine, using ISOLUTE<sup>\*</sup> SLE+ protocol on 200  $\mu$ L capacity plate format (left) and 400  $\mu$ L capacity column format (right). Concentrations are 2.5, 5, 7.5, 10, 20 and 50  $\mu$ g/mL. r<sup>2</sup> values are greater than 0.999.




Figure 4. GC/MS chromatography for urine (Cal 1) spiked at 2.5 ng/mL. Compared to other more traditional solid phase extraction procedures, this ISOLUTE\* SLE+ method results in a baseline with reduced noise and thus offers greater confidence when qualifying GHB.



#### Additional Information

0.2% formic acid (aq) is prepared by adding 100  $\mu L$  concentrated formic acid (commercially available 98%) to 49.9 mL HPLC grade water

#### **Ordering Information**

Part Number	Description	Quantity
820-0200-P01	ISOLUTE° SLE+ 200 $\mu L$ Supported Liquid Extraction Plate	1
820-0055-B	ISOLUTE° SLE+ 400 $\mu L$ Sample Volume Columns	50
PPM-48	Biotage® PRESSURE+ 48 Positive Pressure Manifold	1
SD-9600-DHS-EU	Biotage $^{\circ}$ SPE Dry Sample Concentrator System 220/240 V	1
SD-9600-DHS-NA	Biotage $^{\circ}$ SPE Dry Sample Concentrator System 100/120 V	1
C103198	TurboVap° LV, 100/120V	1
C103199	TurboVap® LV, 220/240V	1

For the latest application notes visit www.biotage.com

#### EUROPE

Main Office: +46 18 565900 Toll Free: +800 18 565710 Fax: +46 18 591922 Order Tel: +46 18 565710 Order Fax: +46 18 565705 order@biotage.com Support Tel: +46 18 56 59 11 Support Fax: +46 18 56 57 11 eu-1-pointsupport@biotage.com

#### NORTH & LATIN AMERICA

Main Office: +1 704 654 4900 Toll Free: +1 800 446 4752 Fax: +1 704 654 4917 Order Tel: +1 704 654 4900 Order Fax: +1 434 296 8217 ordermailbox@biotage.com Support Tel: +1 800 446 4752 Outside US: +1 704 654 4900 us-1-pointsupport@biotage.com

#### JAPAN

Tel: +81 3 5627 3123 Fax: +81 3 5627 3121 jp\_order@biotage.com jp-1-pointsupport@biotage.com

#### CHINA

Tel: +86 21 2898 6655 Fax: +86 21 2898 6153 cn\_order@biotage.com cn-1-pointsupport@biotage.com

To locate a distributor, please visit our website at www.biotage.com



© 2014 Blotage. All rights reserved. No material may be reproduced or published without the written permission of Biotage. Information in this document is subject to change without notice and does not represent any commitment from Biotage. E&OE. Product and company names mentioned herein may be trademarks or registered trademarks and/or service marks of their respective owners, and are used only for explanation and to the owners' benefit, without intent to infringe. For more information visit www.biotage.com.

